Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.Antoni Ribas, Paolo A. Ascierto, Georgina V. Long et al.|Journal of Clinical Oncology|2022Cited by 8
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Reinhard Dummer, Georgina V. Long, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2024Cited by 4